Skip to main content
TipRanks
Go Ultimate75% OFF

ICU Medical (IC7) AI Stock Analysis

0 Followers
DE:IC7

ICU Medical

(Frankfurt:IC7)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong cash generation and deleveragingStrong operating and free cash flow gives ICU Medical internal funding capacity for product development, integration and debt reduction. The concurrent decline in leverage improves financial resilience and should support more flexible capital allocation over the next several quarters.
Negative Factors
Vital Care contraction and logistics disruptionThe Vital Care decline shows that integration and distribution changes can disrupt execution and product availability across the portfolio. Continued weakness would dilute the benefit of stronger Infusion Systems performance and pressure consolidated growth and mix.

ICU Medical (IC7) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%40%50%DE:IC7+42.61%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.48B
Dividend Yield
―
Average Volume (3M)
40
Price to Earnings (P/E)
74.4
Beta (1Y)
0.53
Revenue Growth
-10.78%
EPS Growth
―
Country
Germany
Employees
13,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

ICU Medical Business Overview & Revenue Model

Company Description

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion...

ICU Medical Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:10.81%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call was broadly positive. The company reported solid revenue, EBITDA, EPS and free cash flow performance; record results in Infusion Systems and Consumables; improving gross margins; lower integration spending; debt reduction; and guidance toward the high end of its ranges. These strengths outweighed the stated challenges, including Vital Care's decline, logistics disruptions, tariff and FX pressures, ongoing remediation spending and approval timing for certain products.

Positive Updates

Solid Q3 Revenue and Earnings Growth
Q3 revenue was $556 million, representing 5% organic growth and 4% reported growth. Adjusted EBITDA increased 8% year over year to $114 million, with a 20.5% EBITDA margin, while adjusted diluted EPS rose 20% to $2.44 from $2.03.

Negative Updates

Logistics Consolidation Disruptions
The consolidation of legacy Smiths physical distribution and logistics into a common network caused operational bumps, particularly in international markets. The company had to prioritize Infusion Systems products, followed by Infusion Consumables and Vital Care, resulting in a slightly different revenue mix even though management said there was no net impact to total company revenue expectations.

Company Guidance

ICU Medical expects Consumables to deliver mid-single-digit growth for 2026 and Infusion Systems to be at least high single digits for the full year 2026, while Vital Care will have a larger year-over-year decrease than previously mentioned; full-year adjusted EBITDA is expected towards the higher end of the previously provided guidance range of $415 million to $435 million and adjusted EPS towards the higher end of $8.60 to $9, with no changes to guidance for gross margin rate, operating expenses or interest expense. Full-year CapEx guidance was lowered from $85 million to $75 million, although fourth-quarter CapEx spending is expected to be meaningfully higher than the average quarterly spend to date; year-to-date free cash flow was $173 million versus an original full-year target of $150 million, Q4 free cash flow won't be as strong as Q3, and the company does not expect a material benefit from tariff refunds. The company expects to finish 2026 slightly below 2x net leverage, continue to pay down debt in Q4, and remains focused on achieving a gross margin target of 43% by the time we exit 2027.

ICU Medical Risk Analysis

ICU Medical disclosed 40 risk factors in its most recent earnings report. ICU Medical reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

0 New Risks

ICU Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:IC7 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MMSIMMSI71Outperform$5.19B32.209.65%―9.34%33.77%
BDXBDX63Neutral$59.39B52.544.64%1.82%-7.40%-28.89%
TFXTFX57Neutral$6.15B18.649.74%0.88%-29.30%―
ANGOANGO52Neutral$499.19M-15.03-19.25%―8.20%-0.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BAXBAX46Neutral$13.35B-18.70-11.62%0.16%5.33%-164.67%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%DE:IC7ANGOBAXBDXMMSITFXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:IC7 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:IC7ICU Medical164.0048.0041.38%
ANGOAngiodynamics, Inc.11.78-0.10-0.84%
BAXBaxter International Inc25.547.4340.99%
BDXBecton, Dickinson and Co216.4769.0146.80%
MMSIMerit Medical86.352.182.59%
TFXTeleflex157.1050.7247.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.